Genexine said that the Ministry of Food and Drug Safety has approved its trials for a jet injector-type Covid-19 vaccine.
|Genexine has won the regulatory approval to conduct a phase 2a clinical trial for a jet injector-type Covid-19 vaccine. (Genexine)|
"The approval marks the world's first trial for a jet injector method Covid-19 vaccine," the company said. "The method has the advantage of excellent user convenience and portability. As the vaccines are injected without needles, patients who fear needles, such as children, can comfortably and safely receive the Covid-19 vaccine."
Genexine plans to enter the phase 2a clinical trial after selecting the most appropriate administration method by comparing and analyzing the safety and immunogenicity for two types of injection methods -- electroporation and jet injector.
The dosing method's expansion will also increase the number of participants partaking in phase 1 clinical trial from 40 to 60, with no changes made to the phase 2a clinical trials.
"The company's Covid-19 vaccine is intended for all age groups, from children to the elderly. The company expects that a convenient and safe jet injector administration method will increase the accessibility of the vaccine," Genexine CEO Sung Young-chul said.